CellPhire
Rockville
About CellPhire
Cellphire has developed a proprietary method for the stabilization of blood in the dry state Current efforts and product development are aimed toward stabilized platelets for advanced wound care, transfusion, and reagent products for clinical and research diagnostics. We have been able to stabilize and modify platelets into a hemostatic agent that can be stored well beyond the current limit of 5 days. Platelets cannot be stockpiled and shortages occur because of this extremely short shelf life. These shortages can interrupt the treatment of cancer patients and actively bleeding surgical or trauma patients. The fragility of the national supply of platelets is a topic of discussion of several task forces and agencies planning the nation's response to a pandemic such as avian influenza. This and other natural or manmade disasters would interrupt or exceed the available supply of platelets that is needed to maintain an adequate supply or treat bleeding casualties.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $21.0M
- Funding stage: Early Stage Venture
- Last round: Debt Financing (Dec 2025)
- Website: cellphire.com
- Phone: 2402681145
Industries & Categories
Biotechnology, Health Care, Health Diagnostics, Medical
Social Profiles
Canonical: https://fsome.com/organization/cellphire-26206 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.